On November 1, 2024, Santo J. Costa, a member of the Board of Directors of Aquestive Therapeutics, Inc. (the “Company”) and the Chairman of the Compensation Committee thereof (the “Compensation Committee”), notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective November 4, 2024.
Arty Straehla has notified the Company’s Board of Directors (the “Board”) on November 6, 2024 of his decision to retire as the Chief Executive Officer of the Company, effective as of December 31, 2024.
Departed
(interim)
Christopher Andrews
Interim Chief Financial Officer and Chief Operating Officer
Collective Audience, Inc.
Effective
2024-11-01
Successor
Gerald Garcia
Filed
November 7, 2024, 6:59 PM ET
Mr. Garcia replaces Mr. Christopher Andrews as Chief Financial Officer who resigned from his role as Interim Chief Financial Officer and Chief Operating Officer on November 1, 2024.
On November 7, 2024, the Company announced that Jay Geldmacher, the Company’s President and Chief Executive Officer, has informed the Company’s Board of Directors (the “Board”) of his intention to retire
Chad M. Wheeler, Group President for the Company's Fleet Segment, notified the Company on February 29, 2024, of his decision to resign from his position as VSE’s Group President for the Fleet Segment, with an effective date to be set later in 2024.
Departed
Ian Eckert
Vice President, Corporate Controller and Chief Accounting Officer
On November 1, 2024, Alamo Group Inc. (the “Company”) was informed by Ian Eckert , the Company’s Vice President, Corporate Controller and Chief Accounting Officer and principal accounting officer of the Company (“PAO”) , that he is resigning from such position effective no later than January 3, 2025 to pursue another opportunity.
On November 4, 2024, John Morrison notified the Company of his decision to resign from his role as Chief Financial Officer of the Company, effective November 11, 2024 (the "Effective Date").
Departed
Jane F. Barlow
Director
Viracta Therapeutics, Inc.
Effective
2024-10-31
Filed
November 6, 2024, 6:59 PM ET
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
Departed
Stephen Rubino
Director
Viracta Therapeutics, Inc.
Effective
2024-10-31
Filed
November 6, 2024, 6:59 PM ET
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
Departed
Sam Murphy
Director
Viracta Therapeutics, Inc.
Effective
2024-10-31
Filed
November 6, 2024, 6:59 PM ET
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
Departed
Jane Chung
Director
Viracta Therapeutics, Inc.
Effective
2024-10-31
Filed
November 6, 2024, 6:59 PM ET
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
Departed
Gerhard Ziems
Group Chief Financial Officer and Head of Strategic Investment
On November 5, 2024 (November 6, 2024 in Australia), Mr. Gerhard Ziems informed Coronado Global Resources Inc. (the “Company”) that he is resigning as Group Chief Financial Officer and Head of Strategic Investment to pursue new opportunities.
Departed
Julie Zeiler
Executive Vice President and Chief Financial Officer
IROBOT CORP
Effective
2024-12-02
Successor
Karian Wong
Filed
November 6, 2024, 6:59 PM ET
On November 4, 2024, Julie Zeiler stepped down as Executive Vice President and Chief Financial Officer of the Company, effective December 2, 2024.
Departed
Michael W. Sutherlin
Director
RADIUS RECYCLING, INC.
Effective
2024-11-03
Filed
November 6, 2024, 6:59 PM ET
On November 3, 2024, Michael W. Sutherlin notified Radius Recycling, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”) effective as of November 3 rd .
On November 6, 2024, the Company announced that, on November 4, 2024, Mr. Richard M. McVey, our Executive Chairman of the Board of Directors (the “ Board ”), informed the Board that he will retire from his position and as a member of the Board, effective December 31, 2024.
Departed
Scott W. Kingsmore
Senior Executive Vice President, Chief Financial Officer and Treasurer
Scott W. Kingsmore, the Company’s current Senior Executive Vice President, Chief Financial Officer and Treasurer, will be departing the Company effective as of December 31, 2024.
On November 3, 2024, Mojdeh Poul informed the board of directors (the “Board”) of Stanley Black & Decker, Inc. (the “Company”) of her decision not to stand for re-election as a director of the Company at the Company’s 2025 annual meeting of shareholders (the “2025 Annual Meeting”).
Tom Einar Jensen, the Company’s Chief Executive Officer (“ CEO ”), would be resigning from his position as CEO and as a director of the Company, effective immediately
On November 4, 2024, Seah Lim, M.D., Ph.D., resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) for personal reasons and expressed his best wishes to the company.
As previously disclosed, on September 18, 2024, Shrisha Radhakrishna resigned from his positions as Chief Technology Officer and Chief Product Officer of LegalZoom to pursue other opportunities, with such resignation originally to be effective November 15, 2024. Mr. Radhakrishna’s resignation is now effective November 4, 2024.
(a) David M. Shaffer has advised EnerSys of his intention to retire as Chief Executive Officer of EnerSys and member of its Board of Directors effective May 22, 2025,
Departed
Jacques N. Gordon
Director
JLL Income Property Trust, Inc.
Effective
2024-11-05
Successor
Lisa L. Kaufman
Filed
November 6, 2024, 6:59 PM ET
On November 5, 2024, Jacques N. Gordon tendered his resignation from his position as a member of the Board of Directors (the "Board") of JLL Income Property Trust, Inc. (the "Company"), effective as of November 5, 2024.
On November 6, 2024, the Company announced that Mr. James Brady, Executive Vice President and Chief Operating Officer will be exiting the Company effective November 29, 2024.
W. Andrew Adams notified National Health Investors, Inc. (the “Company”) of his decision to retire from his position as Chairperson and a member of the Board of Directors (the “Board”) effective December 31, 2024.
On October 30, 2024, Wetteny Joseph, a member of the Board of Directors (the “Board”) of Ashland Inc. (the “Company”), notified the Company of his decision to not stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
On October 31, 2024, in connection with the previously announced retirement of Frank Pelzer, Executive Vice President and Chief Financial Officer of F5, Inc. (the “Company”), the Company and Mr. Pelzer entered into a Transition Agreement (the “Transition Agreement”).
Boris Illetschko resigned from his position as the Senior Vice President, Chief Operating Officer
Departed
Hector Ruiz
General Counsel and Corporate Secretary
Canoo Inc.
Effective
2024-10-31
Successor
Sean Yan
Filed
November 5, 2024, 6:59 PM ET
On October 31, 2024, Greg Ethridge, the Chief Financial Officer of Canoo who previously served as the CFO of Canoo’s SPAC sponsor Hennessey Capital before transitioning to the Company’s Board as the SPAC’s representative and Hector Ruiz, General Counsel and Corporate Secretary of Canoo, notified Canoo of their resignations.
Departed
Greg Ethridge
Chief Financial Officer
Canoo Inc.
Effective
2024-10-31
Successor
Kunal Bhalla
Filed
November 5, 2024, 6:59 PM ET
On October 31, 2024, Greg Ethridge, the Chief Financial Officer of Canoo who previously served as the CFO of Canoo’s SPAC sponsor Hennessey Capital before transitioning to the Company’s Board as the SPAC’s representative and Hector Ruiz, General Counsel and Corporate Secretary of Canoo, notified Canoo of their resignations.
On November 1, 2024, Dr. Hideki Garren provided Coya Therapeutics, Inc. (the “Company”) with notice of his resignation from the Board of Directors, effective immediately.
Raymond Chang resigned as a member of the Board of Directors (the “Board”) of the Company and any subsidiaries and as President and Chief Executive Officer of the Company
Nandita V. Berry and David F. Taylor will step down from the Board effective immediately.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.